Abstract
New technologies and equipment for medicine analysis and diagnostics have always been critical in clinical medication and pharmaceutical production. Especially in the field of traditional Chinese medicine (TCM) where the chemical composition is not fully clear, cross-device analysis and identification using the same technology can sometimes even lead to misjudgments. Akebia species, capable of inducing heat clearing, diuresis, and anti-inflammatory effects, show great potential in clinical applications. However, the three commonly used species differ in pharmacological effects and therefore should not be used interchangeably. We proposed a method combining LIBS with random forest for species identification and established a modeling and verification scheme across device platforms. Spectra of three Akebia species were collected using two LIBS systems equipped with spectrometers of different resolutions. The data acquired from the low-resolution spectrometer were used for model training, while the data from the high-resolution spectrometers were used for testing. A spectral correction and feature selection (SCFS) method was proposed, in which spectral data were first corrected using a standard lamp, followed by feature selection via analysis of variance (ANOVA) to determine the optimal number of discriminative features. The highest classification accuracy of 80.61% was achieved when 28 features were used. Finally, a post-processing (PP) strategy was applied, where abnormal spectra in the test set were removed using density-based spatial clustering of applications with noise (DBSCAN), resulting in a final classification accuracy of 85.50%. These results demonstrate that the proposed "SCFS-PP" framework effectively enhances the reliability of cross-instrument data utilization and expands the applicability of LIBS in the field of TCM.